A baseline manufacturing route for the (S)-enantiomer of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole—the direct precursor to the dopaminergic API Pramipexole dihydrochloride monohydrate—relies on fractional crystallization of diastereomeric salts formed with (+)-tartaric acid. During this resolution, R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole is concentrated in the mother liquors, where it represents a recoverable chiral pool that can be racemized and resubmitted to the resolution sequence. Industrial-scale racemization typically proceeds by heating the mother liquor in a polar protic solvent at 70–85 °C in the presence of a mild aldehyde catalyst (e.g., salicylaldehyde at 0.05–0.10 molar equivalents) under nitrogen, achieving re-racemization by Schiff-base-mediated proton exchange at the stereogenic center at C-6. Repetition of this cycle across three to five re-racemization loops pushes the cumulative molar yield of (S)-enantiomer beyond 85% relative to the starting racemic 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole. Residual chiral purity of the racemized intermediate must fall within R:S = 50.0 ± 1.5% as determined by chiral HPLC using a polysaccharide-based column (amylose tris(3,5-dimethylphenylcarbamate), 250 × 4.6 mm, mobile phase hexane/ethanol/diethylamine) referenced against USP Pramipexole Related Compound B system suitability criteria. Plant-scale batch records from multipurpose multi-reactor facilities (glass-lined, 6,300 L nominal reactor volume) document that the racemization mass efficiency is critically dependent on pre-stripping of the (+)-tartaric acid counterion to below 0.2 wt%; otherwise, residual acid catalyzes irreversible amino-oxazoline formation during thermal treatment, which generates an unrecoverable dimeric by-product detectable at RRT 1.36 under the aforementioned chiral conditions.
Compliance boundaries are defined by ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients, sections 8.1–8.5 on recovery of materials) and the regional implementation of ICH Q11 concerning starting material designation; the recovered racemate is typically accepted as an intermediate when a batch history of 20 consecutive lots confirms consistent impurity profiles with ≤0.15% total unspecified impurities by area normalization. The end-product remains (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole dihydrochloride, the immediate precursor to Pramipexole, which is subsequently alkylated with 1-bromopropane under phase-transfer conditions to yield the final drug substance meeting Ph.Eur. 10.0 monograph 2413 and USP 43 monographs.
What chromatographic fidelity limits apply when this chiral isomer is deployed as a reference marker?
Pharmacopoeial monographs for Pramipexole explicitly list the (R)-enantiomer as a specified impurity (Ph.Eur. Impurity G; USP Pramipexole Related Compound B), with an acceptance criterion of ≤ 0.5% in the drug substance. Certified reference material of R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole dihydrochloride, typically standardized to ≥ 98.5% purity (on anhydrous, solvent-free basis) by qNMR against a certified internal standard (e.g., 1,4-dinitrobenzene), is indispensable for system suitability testing and external calibration in quality control release laboratories. Integration of the enantiomeric purity validation protocol adheres to ICH Q2(R2) guidelines: linearity is established across 0.1%–1.5% of the nominal analyte concentration (r² ≥ 0.9995), the limit of quantitation defined at a signal-to-noise ratio of 10:1 consistently falls below 0.05%, and intermediate precision across three analysts on three days returns an RSD of ≤ 6.0% for six replicate injections at the specification level. Injection solutions are prepared by dissolving the reference standard in a diluent composition of acetonitrile/water/trifluoroacetic acid (20:80:0.1 v/v/v) at a concentration of 0.50 mg/mL, corresponding to an injection mass of 5.0 µg on-column for a 10 µL injection volume. The validated HPLC procedure relies on a chiral stationary phase, typically immobilized amylose tris(3-chloro-4-methylphenylcarbamate) in a 150 × 4.6 mm, 5 µm column configuration, thermostatted at 35 ± 0.5 °C, with UV detection at 264 nm and isocratic elution at 1.0 mL/min. Any misidentification risk arising from co-eluting process impurities—most critically the des-propyl precursor (2,6-diamino-4,5,6,7-tetrahydrobenzothiazole)—is mitigated by a peak purity assessment exceeding 995 (photodiode array threshold) and confirmation of retention time relative to the primary peak within a tolerance of ± 0.05 min. Reporting units conform to the European Pharmacopoeia external standard calculation formula for specified impurities, with corrections applied for salt and water content. The terminal object of this analytical workflow is the issuance of a Certificate of Analysis affirming that the batch of Pramipexole dihydrochloride monohydrate is compliant for release, thereby coupling the reference-material integrity directly to the batch disposition decision.
Latent curing in single-component epoxy underfills: stoichiometry windows and gelation behavior
When formulated as a micronized latent hardener for single-component epoxy systems designed for flip-chip underfill encapsulation, R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole—owing to the steric shielding of its secondary amine environment by the tetrahydrobenzothiazole ring—exhibits a characteristic onset-of-cure temperature near 128 °C (DSC ramp at 10 K/min, sealed aluminum pan) and a peak exotherm at 154 °C, allowing safe storage at −15 °C for 12 months with viscosity rise limited to ≤ 15% of initial value. The stoichiometric addition ratio is calculated based on the amine hydrogen equivalent weight (AHEW) of 42 g/eq per the Jeffamine reference method (ISO 9702:1996, modified for solid hardeners) and is combined with bisphenol-F diglycidyl ether (EEW 168 g/eq) at an index of 1.0 ± 0.05. Designed for capillary flow underfill dispensing, the formulation includes 62–68 wt% silica filler (median particle size 0.5 µm, surface-treated with phenylaminosilane coupling agent to satisfy IPC J-STD-020 moisture sensitivity level 3), enabling a cured glass transition temperature of 132 °C after a step-cure regime (130 °C for 30 min + 160 °C for 60 min) measured in TMA penetration mode per IPC-TM-650 method 2.4.24c. In-line dispensing platforms operating with an auger valve and a nozzle diameter of 150 µm maintain a volume per dot of 0.8–1.2 mg with ±6% repeatability; the molecular structure of the tetrahydrobenzothiazole hardener contributes a reduced tendency to absorb atmospheric moisture during open pot-life phases compared to aliphatic polyamines, noted in production logs as a reduction of air void count from 3.2 voids/mm² to ≤ 0.8 voids/mm² in the post-vacuum reflow image (X-ray imaging, 10 µm focal spot). Final package reliability is specified under JEDEC JESD22-A104 thermal cycling (−40 °C to +125 °C, 1,000 cycles) with electrical daisy-chain daisy continuity failure defined as a resistance increase exceeding 20%; pass criteria for this amine-hardened system achieves 0/76 failures after preconditioning at MSL 3. The terminal product forms are chip-scale packages and ball-grid-array substrates for application processors and automotive microcontrollers, where compliance with AEC-Q100 Grade 1 temperature ranges is required.
Copper-film passivation in alkaline chemical mechanical planarization slurries
Owing to the strong coordination affinity of the benzothiazole moiety toward Cu(I) surfaces, coupled with the improved aqueous solubility conferred by the two primary amino groups, R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole can function as a passivation agent in colloidal silica-based slurries formulated for copper damascene CMP at pH 9.0–10.2. The additive is incorporated in the dilution tank at a working concentration of 0.08–0.35 wt% relative to the total slurry volume (post-1:2.5 water dilution of the concentrated slurry), blended with 6 wt% fumed silica abrasive (BET surface area 95 m²/g) and 1.2 wt% glycine as a complexant/buffer per the slurry supplier’s operating sheet. Electrochemical characterization via potentiodynamic polarization in a three-electrode flat cell (copper disc working electrode, Ag/AgCl reference, scan rate 5 mV/s, aerated slurry at 24 ± 1 °C) reveals that the addition of 0.15 wt% shifts the corrosion potential from −340 mV to −210 mV and reduces the corrosion current density from 22 µA/cm² to 2.1 µA/cm², with the corresponding Tafel extrapolation validated per ASTM G102-89(2015)e1. On a production-scale polisher (four-zone, single-platen, 300 mm wafer configuration, downforce 1.8 psi, table and carrier rotation 93/87 rpm), the immediate consequence is a reduction in static etch rate from 450 Å/min (no passivator) to < 28 Å/min while sustaining a copper removal rate of 5,800–6,400 Å/min, monitored by eddy-current metrology at 49-point polar mapping. An undesirable side-effect, documented in split-lot evaluations across 2,200 wafers per condition, emerges at passivator loading exceeding 0.40 wt%: the formation of a polymeric Cu(I)-benzothiazole film resistant to post-CMP cleaning, causing organic-residue defect counts measured by laser scanning confocal microscopy to increase from a baseline of < 15 defects/wafer (≤ 0.3 µm size bin) to 340–620 defects/wafer. Accordingly, a processing window bounded at 0.10–0.25 wt% is enforced through automated density-meter feedback control loops to maintain the surface roughness of the copper lines after cleaning below 8 Å RMS as quantified under atomic force microscopy (10 × 10 µm scan) and referenced against SEMI C1-0316 guidelines for copper wiring structures. The finished article at the wafer scale serves interconnection layers of logic nodes at 7 nm and 5 nm design rules, and the consumable slurry must comply with all restriction-of-use declarations under EU RoHS (2011/65/EU) for semiconductor process chemicals.
When a sulfur-bridged acceleration system incorporates this heterocycle as a secondary stabilizer
Standard sulfur-cure packages for NR/BR tread compounds (natural rubber/polybutadiene blend at 70:30 phr) incorporate the combination of a sulfenamide accelerator (N-cyclohexyl-2-benzothiazyl sulfenamide, CBS, 1.2 phr) and elemental sulfur (1.8 phr) to extract crosslink densities in the range of 1.4–1.6 × 10⁻⁴ mol/cm³. R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole, when co-milled with the CBS batch at a ratio of 0.15–0.35 phr, acts as an antioxidant retainer rather than a primary accelerator: it chelates soluble copper and manganese ions (present at 2–8 ppm from natural rubber latex coagulum) that would otherwise catalyze oxidative chain scission during service, shifting the oxidative induction time measured by differential scanning calorimetry at 180 °C (OIT per ISO 11357-6:2018, 50 mL/min O₂ flow) from 8.2 min (no scavenger) to 23.6 min. Mixing is performed on a tangential intermeshing internal mixer (net volume 270 L) with ram pressure of 6 bar, drop temperature controlled below 145 °C to avoid premature aminolysis of the polysulfidic bridges. Standard compliance for the final vulcanizate is verified under UN ECE Regulation 54 for commercial vehicle tyres, incorporating the dynamic mechanical properties of the tread tested according to ASTM D5992-96(2018) at 60 °C and 10 Hz (tan δ 0.14 ± 0.02). The tetrahydrobenzothiazole diamine is introduced as a pre-dispersed masterbatch in EPDM binder (50:50 ratio) to ensure metering accuracy at the feed throat; failure to pre-disperse results in undissolved agglomerates observable as dark specks (> 0.5 mm) on a laboratory two-roll mill at a setting of 0.5 mm nip and 70 °C. In cured tread cap co-extrudates, the amine-modifier influences adhesion to the nylon cord carcass because it effectively competes with the resorcinol-formaldehyde-latex (RFL) dip for copper-activated zinc oxide at the interface, requiring a reduction of the cobalt stearate adhesion promoter to 0.5 phr to maintain pull-out force above 185 N/cord (ASTM D4776). The final product form is a radial truck/bus tyre tread segment destined for retreading operations or original equipment fitments under Regulation 117 rolling resistance class B or above.
A subtler demand pathway emerges when the diamine is employed as a building block in the preparation of C₂-symmetric chiral bis(oxazoline) ligands for enantioselective allylic oxidation. Starting from R-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole, condensation with a substituted benzoyl chloride in the presence of triethylamine at 0–5 °C in dichloromethane (anhydrous, < 50 ppm H₂O) produces the bis-amide intermediate, which is subsequently cyclized with methanesulfonic acid in toluene under azeotropic water removal at 110 °C to afford the bis(oxazoline) ligand. After column chromatography (silica gel 60, hexane:ethyl acetate 3:1), the ligand is isolated in 61–68% yield with an enantiomeric excess exceeding 99.5% (chiral SFC, CO₂/methanol gradient). When this ligand is applied in a copper(I)-catalyzed asymmetric Kharasch–Sosnovsky reaction with cyclohexene and tert-butyl perbenzoate, the R-configuration of the bis(oxazoline) framework directs the attack to the pro-(S) face of the allylic intermediate, affording the (R)-benzoate ester in 74% ee as determined by GC on a β-cyclodextrin column (film thickness 0.25 µm, 30 m × 0.25 mm). The laboratory-scale protocol is encapsulated in a technology-transfer package referencing OECD Guideline 503 for metal-catalyzed oxidation scale-up risk assessment, though commercial-scale tonnage demand for this specific ligand remains limited to early-phase pharmaceutical contract research. The terminal entities are chiral allylic esters serving as intermediates for natural product total syntheses and fragrance ingredients, with product release governed by the monograph of USP general chapter <795> or <797> where compounded.
